Syngene International Limited
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and anal… Read more
Syngene International Limited (SYNGENE) - Net Assets
Latest net assets as of September 2025: ₹47.35 Billion INR
Based on the latest financial reports, Syngene International Limited (SYNGENE) has net assets worth ₹47.35 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹65.42 Billion) and total liabilities (₹18.07 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹47.35 Billion |
| % of Total Assets | 72.38% |
| Annual Growth Rate | 23.74% |
| 5-Year Change | 67.53% |
| 10-Year Change | 348.97% |
| Growth Volatility | 15.67 |
Syngene International Limited - Net Assets Trend (2010–2025)
This chart illustrates how Syngene International Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Syngene International Limited (2010–2025)
The table below shows the annual net assets of Syngene International Limited from 2010 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹47.27 Billion | +11.02% |
| 2024-03-31 | ₹42.58 Billion | +17.68% |
| 2023-03-31 | ₹36.18 Billion | +9.72% |
| 2022-03-31 | ₹32.98 Billion | +16.88% |
| 2021-03-31 | ₹28.21 Billion | +29.67% |
| 2020-03-31 | ₹21.76 Billion | +10.54% |
| 2019-03-31 | ₹19.68 Billion | +14.42% |
| 2018-03-31 | ₹17.20 Billion | +21.75% |
| 2017-03-31 | ₹14.13 Billion | +34.22% |
| 2016-03-31 | ₹10.53 Billion | +24.61% |
| 2015-03-31 | ₹8.45 Billion | +28.15% |
| 2014-03-31 | ₹6.59 Billion | +27.13% |
| 2013-03-31 | ₹5.19 Billion | +74.73% |
| 2012-03-31 | ₹2.97 Billion | +34.48% |
| 2011-03-31 | ₹2.21 Billion | +14.06% |
| 2010-03-31 | ₹1.94 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Syngene International Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1987.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹38.82 Billion | 82.13% |
| Common Stock | ₹4.03 Billion | 8.52% |
| Other Comprehensive Income | ₹2.04 Billion | 4.31% |
| Other Components | ₹2.38 Billion | 5.04% |
| Total Equity | ₹47.27 Billion | 100.00% |
Syngene International Limited Competitors by Market Cap
The table below lists competitors of Syngene International Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nanjing Sunlord Electronics Corporation LTD
SHE:300975
|
$834.47 Million |
|
Nava Bharat Ventures Limited
NSE:NAVA
|
$834.67 Million |
|
Amoy Diagnostics Co Ltd
SHE:300685
|
$834.75 Million |
|
Konka Group Co Ltd
SHE:000016
|
$834.83 Million |
|
SPAREBANK 1 SOROST-NORGE
F:EZ4
|
$834.38 Million |
|
Jack Sewing
SHG:603337
|
$834.34 Million |
|
Beijing Urban Construction Investment & Development Co Ltd
SHG:600266
|
$833.98 Million |
|
Changjiang & Jinggong Steel Building Group Co Ltd
SHG:600496
|
$833.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Syngene International Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 42,577,000,000 to 47,268,000,000, a change of 4,691,000,000 (11.0%).
- Net income of 4,962,000,000 contributed positively to equity growth.
- Dividend payments of 503,000,000 reduced retained earnings.
- Share repurchases of 5,000,000 reduced equity.
- New share issuances of 5,000,000 increased equity.
- Other comprehensive income decreased equity by 43,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹4.96 Billion | +10.5% |
| Dividends Paid | ₹503.00 Million | -1.06% |
| Share Repurchases | ₹5.00 Million | -0.01% |
| Share Issuances | ₹5.00 Million | +0.01% |
| Other Comprehensive Income | ₹-43.00 Million | -0.09% |
| Other Changes | ₹275.00 Million | +0.58% |
| Total Change | ₹- | 11.02% |
Book Value vs Market Value Analysis
This analysis compares Syngene International Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.50x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 71.90x to 3.50x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-03-31 | ₹5.72 | ₹411.05 | x |
| 2011-03-31 | ₹6.52 | ₹411.05 | x |
| 2012-03-31 | ₹8.76 | ₹411.05 | x |
| 2013-03-31 | ₹14.74 | ₹411.05 | x |
| 2014-03-31 | ₹16.75 | ₹411.05 | x |
| 2015-03-31 | ₹21.46 | ₹411.05 | x |
| 2016-03-31 | ₹26.65 | ₹411.05 | x |
| 2017-03-31 | ₹35.78 | ₹411.05 | x |
| 2018-03-31 | ₹43.45 | ₹411.05 | x |
| 2019-03-31 | ₹49.62 | ₹411.05 | x |
| 2020-03-31 | ₹54.65 | ₹411.05 | x |
| 2021-03-31 | ₹70.42 | ₹411.05 | x |
| 2022-03-31 | ₹81.84 | ₹411.05 | x |
| 2023-03-31 | ₹89.64 | ₹411.05 | x |
| 2024-03-31 | ₹105.92 | ₹411.05 | x |
| 2025-03-31 | ₹117.59 | ₹411.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Syngene International Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.50%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.62%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 1.44x
- Recent ROE (10.50%) is below the historical average (17.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 15.71% | 11.52% | 0.52x | 2.65x | ₹110.50 Million |
| 2011 | 12.32% | 8.61% | 0.63x | 2.28x | ₹51.30 Million |
| 2012 | 23.92% | 17.38% | 0.70x | 1.98x | ₹413.20 Million |
| 2013 | 19.69% | 18.56% | 0.76x | 1.40x | ₹502.40 Million |
| 2014 | 26.54% | 20.35% | 0.72x | 1.81x | ₹1.09 Billion |
| 2015 | 20.71% | 20.35% | 0.60x | 1.68x | ₹905.10 Million |
| 2016 | 22.87% | 21.75% | 0.46x | 2.27x | ₹1.36 Billion |
| 2017 | 20.33% | 23.92% | 0.43x | 1.96x | ₹1.46 Billion |
| 2018 | 17.75% | 21.46% | 0.45x | 1.85x | ₹1.33 Billion |
| 2019 | 16.85% | 18.16% | 0.49x | 1.88x | ₹1.35 Billion |
| 2020 | 18.94% | 20.48% | 0.48x | 1.91x | ₹1.95 Billion |
| 2021 | 14.35% | 18.54% | 0.45x | 1.73x | ₹1.23 Billion |
| 2022 | 12.00% | 15.20% | 0.47x | 1.69x | ₹660.40 Million |
| 2023 | 12.84% | 14.54% | 0.55x | 1.61x | ₹1.03 Billion |
| 2024 | 11.98% | 14.62% | 0.57x | 1.44x | ₹842.30 Million |
| 2025 | 10.50% | 13.62% | 0.54x | 1.44x | ₹235.20 Million |
Industry Comparison
This section compares Syngene International Limited's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $4,206,050,808
- Average return on equity (ROE) among peers: 16.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Syngene International Limited (SYNGENE) | ₹47.35 Billion | 15.71% | 0.38x | $834.43 Million |
| Krsnaa Diagnostics Limited (KRSNAA) | $6.69 Billion | 10.23% | 0.31x | $119.95 Million |
| Dr. Lal Path Labs Ltd. (LALPATHLAB) | $1.17 Billion | 38.19% | 0.51x | $1.16 Billion |
| Metropolis Healthcare Limited (METROPOLIS) | $9.91 Billion | 14.42% | 0.52x | $557.10 Million |
| SAI LIFE SCIENCES LTD (SAILIFE) | $8.88 Billion | 1.12% | 1.46x | $1.01 Billion |
| SURAKSHA (SURAKSHA) | $1.26 Billion | 5.10% | 0.36x | $27.40K |
| Thyrocare Technologies Limited (THYROCARE) | $1.02 Billion | 34.10% | 0.34x | $258.97 Million |
| Vijaya Diagnostic Centre Limited (VIJAYA) | $3.59 Billion | 23.52% | 0.51x | $530.99 Million |
| Vimta Labs Limited (VIMTALABS) | $1.12 Billion | 3.75% | 0.29x | $72.56 Million |